Impact Biomedical (IBO) Total Current Liabilities (2022 - 2026)

Impact Biomedical's Total Current Liabilities history runs 5 years deep, the most recent figure standing at $1.7 million for Q1 2026.

• Quarterly Total Current Liabilities fell 83.08% year-over-year to $1.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.7 million (down 83.08% YoY) and the FY2025 annual result came in at $1.2 million, down 88.12% from the prior year.
• Total Current Liabilities was $1.7 million for Q1 2026 at Impact Biomedical, up from $1.2 million in the prior quarter.
• Across five years, Total Current Liabilities topped out at $23.8 million in Q3 2025 and bottomed at $1.1 million in Q3 2024.
• A 5-year average of $11.3 million and a median of $12.1 million in 2023 frame the typical range for Total Current Liabilities.
• Annual changes were most pronounced in 2024 — Total Current Liabilities slumped 90.72% — and 2025, when it jumped 1990.77%.
• Impact Biomedical's Total Current Liabilities stood at $10.6 million in 2022, then grew by 24.01% to $13.1 million in 2023, then slipped by 25.51% to $9.8 million in 2024, then slumped by 88.12% to $1.2 million in 2025, then soared by 45.18% to $1.7 million in 2026.
• Business Quant data shows IBO's Total Current Liabilities at $1.7 million in Q1 2026, $1.2 million in Q4 2025, and $23.8 million in Q3 2025.